BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Oxford Nanopore Technologies Appoints Peter Allen to Board


6/27/2011 10:03:35 AM

OXFORD, UNITED KINGDOM--(Marketwire - June 27, 2011) -

Oxford Nanopore appoints Peter Allen as Non-Executive Director


Monday 27th June 2011, Oxford, UK. Oxford Nanopore Technologies Ltd is
pleased to announce the appointment of Peter Allen ACA to its board.

Peter Allen joins the board of Oxford Nanopore as non executive
Director with broad, senior experience in the life sciences industries.
He currently serves as Non-Executive Chairman on the Boards of
ProStrakan Group plc, Chroma Therapeutics Ltd and Proximagen
Neuroscience plc.

Previously, Peter was Chief Financial Officer of the electronics
company Abacus Group plc from April 2005 until the company was sold to
Avnet Inc in January 2009. Prior to this he was Chief Financial Officer
of Celltech Group plc between 1992 and 2004. In addition to managing
Celltech's flotation process in 1993, Peter played a key role in
several strategic acquisitions, including Chiroscience Group plc,
Medeva plc and Oxford Glycosciences plc. In 2003 Peter was also
appointed Deputy Chief Executive Officer of Celltech until the company
was sold to UCB in 2004.

Oxford Nanopore also announces the retirement of Riccardo Pigliucci
from his role as non executive director, after serving nearly five
years on the board."We are excited to welcome Peter Allen to the Board of
Oxford
Nanopore," said Dr Trevor Nicholls, Chairman of Oxford
Nanopore. "Peter's corporate and financial experience across science
and technology industries will add to the strength of our existing
board. We also extend our thanks to Riccardo Pigliucci for his years of
valuable service to the Company."

Dr Gordon Sanghera, CEO, added, "As Oxford Nanopore transitions to its
next stage of corporate development, Peter will provide invaluable
expertise along the pathway of a fast growth company with a genuinely
disruptive technology. We are looking forward to working with Peter in
this exciting period."

-ends-

Contact: Zoe McDougall, Communications, Oxford Nanopore
media@nanoporetech.com


Oxford Nanopore Technologies
Oxford Nanopore Technologies Ltd is developing a novel technology for
direct, electronic detection and analysis of single molecules using
nanopores. The modular, scalable GridION technology platform is
designed to offer substantial benefits in a variety of applications.

The Company is developing two techniques for DNA sequencing:
Exonuclease Sequencing and StrandSequencing, both of which combine a
protein nanopore with a processive enzyme for the analysis of DNA. The
system is also compatible with the direct analysis ofRNA. Oxford
Nanopore is also developing aProtein Analysistechnology that combines
target proteins with ligands for direct, electronic analysis using
protein nanopores. These nanopore sensing techniques are combined with
the Company's proprietary array chip within theGridIONsystem. The
Company also has collaborations for the development ofsolid-state
nanopores.

Oxford Nanopore has collaborations and exclusive licensing deals with
leading institutions including the University of Oxford, Harvard and
UCSC. The Company has funding programmes in these laboratories to
support the science of nanopore sensing. Oxford Nanopore has licensed
or owns more than 300 patents and patent applications that relate to
many aspects of nanopore sensing from protein nanopores to solid state
nanopores and for the analysis of DNA, proteins and other molecules.
This includes the use of functionalised solid-state nanopores for
molecular characterisation, methods of fabricating solid-state
nanopores and modifications of solid-state nanopores to adjust
sensitivity or other parameters.




                    This information is provided by RNS
          The company news service from the London Stock Exchange

END

Contacts:
RNS
Customer
Services
0044-207797-4400
Email Contact
http://www.rns.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES